Challenges managing treatment related adverse events in acral and mucosal melanomas

Karijn Suijkerbuijk, MD, PhD, UMC Utrecht, Utrecht, The Netherlands, discusses the management of immunotherapy related adverse events in mucosal and acral melanomas. The current treatment for these toxicities is immunosuppressants with high-dose steroids, but this has been linked to a reduction in treatment efficacy. It is suggested that, for some toxicities (such as those relating to the endocrine system or skin), immunosuppressants are unnecessary and should be avoided, whilst for complications such as hepatitis, lower dose steroids are sufficient. In other toxicities such as colitis or neurological toxicity, there is no other option for managing these events, meaning more collaborative initiatives are needed to assess the management of these side effects without compromising treatment effectiveness. This interview took place at the European Society for Medical Oncology (ESMO) Asia 2023 Congress in Singapore.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.